Dotinurad is a newer urate-lowering agent that suppresses uric acid reabsorption through the selective inhibition of urate transporter 1 (URAT1) in the proximal renal tubules [6], and it was first approved in Japan in 2020 for the treatment of hyperuricemia, irrespective of gout. Here, SLC22A12 is linked to gout.